BIOCON LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 303.8 INR | +4.17% |
|
+15.94% | +21.51% |
| Apr. 18 | India's Biocon developing its own version of Wegovy, clinical trial likely next year | RE |
| Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
Business Summary
Number of employees: 16,545
Sales per Business
| INR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Biosimilars
49.8
%
| 34,301 | 41.9 % | 55,599 | 49.8 % | +62.09% |
Research
28.1
%
| 25,119 | 30.7 % | 31,392 | 28.1 % | +24.97% |
Generics
22.0
%
| 21,910 | 26.8 % | 24,559 | 22.0 % | +12.09% |
Novels
0.2
%
| 510 | 0.6 % | 192 | 0.2 % | -62.35% |
Sales per region
| INR in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Rest of the World
37.4
%
| 21,468 | 26.2 % | 41,791 | 37.4 % | +94.67% |
United States
37.1
%
| 29,946 | 36.6 % | 41,430 | 37.1 % | +38.35% |
India
15.0
%
| 13,563 | 16.6 % | 16,737 | 15.0 % | +23.40% |
Ireland
10.5
%
| 16,863 | 20.6 % | 11,784 | 10.5 % | -30.12% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Siddharth Mittal
CEO | Chief Executive Officer | 46 | 13-04-30 |
Peter Bains
CEO | Chief Executive Officer | 65 | 22-12-11 |
| Chairman | 71 | 78-11-28 | |
| Chief Tech/Sci/R&D Officer | - | - | |
Mayank Verma
CMP | Compliance Officer | - | 11-12-31 |
Shreehas Tambe
PRN | Corporate Officer/Principal | - | 97-06-30 |
| Corporate Officer/Principal | - | - | |
Akhilesh Nand
LAW | General Counsel | - | 18-02-02 |
Amitava Saha
HRO | Human Resources Officer | 54 | 13-11-30 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | 78-11-28 | |
| Director/Board Member | 69 | 99-12-31 | |
| Director/Board Member | 60 | 18-07-26 | |
| Director/Board Member | 76 | 16-04-26 | |
Peter Bains
CEO | Chief Executive Officer | 65 | 22-12-11 |
Naina Lal Kidwai
BRD | Director/Board Member | 67 | 22-04-27 |
Eric Mazumdar
BRD | Director/Board Member | 31 | 21-10-31 |
Nicholas Haggar
BRD | Director/Board Member | 59 | 23-08-31 |
Siddharth Mittal
CEO | Chief Executive Officer | 46 | 13-04-30 |
| Director/Board Member | - | 23-07-25 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 1,196,804,982 | 446,383,305 ( 37.30 %) | 0 | 37.30 % |
Holdings
| Name | Equities | % | Valuation |
|---|---|---|---|
| 219,185,608 | 54.52% | 1,844,100,578 $ | |
EQUILLIUM, INC. 6.57% | 2,316,134 | 6.57% | 5,350,270 $ |
Company contact information
Biocon Ltd.
20th KM, Hosur Road Electronics City
560100, Bangalore
+91 80 2808 2808
http://www.biocon.com
Group companies
| Name | Category and Sector |
|---|---|
Miscellaneous Commercial Services
| |
Biocon Research Ltd.
 Biocon Research Ltd. Pharmaceuticals: MajorHealth Technology Part of Biocon Ltd., Biocon Research Ltd. is an Indian company that develops and sells biotechnology products. The private company is based in Bangalore, India. |
Pharmaceuticals: Major
|
Biocon Sdn. Bhd.
 Biocon Sdn. Bhd. Pharmaceuticals: MajorHealth Technology Biocon Sdn. Bhd. manufactures insulin products. It provides research and development activities of biopharmaceutical products. The company was founded in 2010 and is headquartered in Nusajaya, Malaysia. |
Pharmaceuticals: Major
|
Biocon Biologics Ltd. (India)
 Biocon Biologics Ltd. (India) Pharmaceuticals: MajorHealth Technology Biocon Biologics India Ltd. operates as a biotech company. It develops treatments for chronicle diseases. The company is headquartered in Bengaluru, India. |
Pharmaceuticals: Major
|
Biocon Pharma Ltd.
 Biocon Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Biocon Ltd., Biocon Pharma Ltd. is an Indian pharmaceutical company that manufactures pharmaceutical preparations. The private company is based in Bangalore, India. |
Pharmaceuticals: Major
|
Biofusion Therapeutics Ltd.
 Biofusion Therapeutics Ltd. BiotechnologyHealth Technology Biofusion Therapeutics Ltd. is an Indian company that focuses on researching and developing new molecules for targeted immuno-oncology therapy. The private company is based in Bangalore, India. |
Biotechnology
|
Biocon Biologics Uk Ltd.
 Biocon Biologics Uk Ltd. Miscellaneous Commercial ServicesCommercial Services Biocon Biologics UK Ltd. is a biopharmaceutical company founded in 2016. The private company is based in London, UK. The British company is focused on finding new and affordable ways to treat diabetes, cancer, and autoimmune diseases. Biocon develops affordable biosimilars, generic formulations, and complex APIs. The company's work in novel biologics and novel targets in large molecules has significant results in diabetes, oncology, and immunology. The company provides access to share information, news, press releases, company statements, media stories, factsheet, leadership profile, reports, video, and image gallery. Syngene, a division of Biocon, is divided into four divisions - drug discovery services, drug development services, manufacturing services, and dedicated R&D centers. |
Miscellaneous Commercial Services
|
Syngene Scientific Solutions Ltd.
|
Sector
Sales per Business
Sales per region
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +21.51% | 4.18B | |
| -2.26% | 103B | |
| +1.41% | 95.71B | |
| +0.79% | 22.02B | |
| -17.84% | 20.9B | |
| -11.11% | 17.85B | |
| -42.83% | 16.21B | |
| -17.63% | 15.52B | |
| +4.55% | 13.86B | |
| +32.11% | 12.04B |
- Stock Market
- Equities
- BIOCON Stock
- Company Biocon Limited
